Phase 2b trial of SJP-002C in MASH and obesity maintenance.
Latest Information Update: 14 Nov 2025
At a glance
- Drugs SJP-002C (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
Most Recent Events
- 14 Nov 2025 New trial record
- 23 Sep 2025 According to a Sen Jam Pharmaceuticals media release, SJP-002C was expanded this year into viability within the metabolic/obesity/MASH therapeutic areas.